# Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

> **NCT04445519** · PHASE3 · COMPLETED · sponsor: **Nicox Ophthalmics, Inc.** · enrollment: 691 (actual)

## Conditions studied

- Open Angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** NCX 470 0.065% (initial phase of trial)
- **DRUG:** Latanoprost 0.005% (initial phase of trial)
- **DRUG:** NCX 470 0.1% (initial phase of trial)
- **DRUG:** NCX 470 0.1% (remainder of trial)
- **DRUG:** Latanoprost 0.005% (remainder of trial)

## Key facts

- **NCT ID:** NCT04445519
- **Lead sponsor:** Nicox Ophthalmics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-01
- **Primary completion:** 2022-09-16
- **Final completion:** 2022-09-16
- **Target enrollment:** 691 (ACTUAL)
- **Last updated:** 2025-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04445519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04445519, "Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04445519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*